Literature DB >> 6196200

Monoclonal antibodies reactive with glioma cell lines derived from experimental brain tumors.

D Stavrou, C Süss, T Bilzer, U Kummer, N De Tribolet.   

Abstract

The production of hybridomas between X63-Ag8.653 myeloma cells and spleen cells from female BALB/c mice immunized with 79FR-G-41 glioma cells is reported. One hundred and six hybridoma clones were obtained secreting monoclonal antibodies (McAbs) against different target cells. Specificity tests (RIA, micro-ELISA) showed that McAbs produced by three hybridoma clones (13GC1, 14BC1, 14FC3) bound 79FR-G-41 glioma cells but did not react with fibroblasts, kidney and brain cells of newborn F344 rats. From the specificity analysis of two McAbs (13GC1, 14BC1) it is evident that these did not only react with 79FR-G-41 cells but also with other glioma cell lines (78FR-G-219, 78FR-G-284, 78FR-G-299 and 78FR-G-344) established from chemically induced rat brain gliomas. These results suggest, in accordance with the findings in human neuroectodermal tumors, the expression of common reactivity antigens in different brain tumors of glial origin. However, the McAbs obtained against experimental rat glioma cells did not recognize glioma cells derived from spontaneous brain tumors of dog or man. Immunofluorescence and immunoperoxidase tests indicate that there is a remarkable heterogeneity among cells of experimental glioma lines with respect to the expression of glioma associated determinants recognized by McAbs. The fact that only a variable number instead of the totality of tumor cells in any asynchronous and uncloned tumor cell population expresses, at a certain time, recognizable antigenic determinants has to be taken into account, particularly if they are considered to be employing McAbs as carrier molecules for diagnostic and therapeutic purposes.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6196200     DOI: 10.1016/0277-5379(93)90014-v

Source DB:  PubMed          Journal:  Eur J Cancer Clin Oncol        ISSN: 0277-5379


  9 in total

1.  Binding specificity of two monoclonal antiglioma antibodies: immunocytochemical studies using a new tissue embedding technique.

Authors:  S Krajewski; G Schwendemann; M Weizsäcker; W Wechsler; N de Tribolet
Journal:  Acta Neuropathol       Date:  1986       Impact factor: 17.088

Review 2.  Monoclonal antibodies in neuro-oncology.

Authors:  D Stavrou
Journal:  Neurosurg Rev       Date:  1990       Impact factor: 3.042

3.  Morphological, immunocytochemical and growth characteristics of three human glioblastomas established in vitro.

Authors:  T Bilzer; D Stavrou; E Dahme; E Keiditsch; K F Bürrig; A P Anzil; W Wechsler
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1991

4.  Localization of experimental glioma grafts by means of iodinated monoclonal antibodies and radionuclide imaging.

Authors:  D Stavrou; W Mellert; T Bilzer; R Senekowitsch; E Keiditsch; P Mehraein
Journal:  Acta Neuropathol       Date:  1985       Impact factor: 17.088

5.  Shared antigenic determinants between human hemopoietic cells and nervous tissues and tumors.

Authors:  H Budka; O Majdic
Journal:  Acta Neuropathol       Date:  1985       Impact factor: 17.088

6.  Presence and absence of virus particles in hybridomas secreting monoclonal antibodies against gliomas.

Authors:  D Stavrou; T Bilzer; T Tsangaris; E Dürr; M Steinecke; A P Anzil
Journal:  J Cancer Res Clin Oncol       Date:  1983       Impact factor: 4.553

7.  Growth inhibition of experimental glioma grafts by monoclonal antibody treatment.

Authors:  D Stavrou; W Mellert; U Mellert; E Keiditsch; K Bise; P Mehraein
Journal:  J Cancer Res Clin Oncol       Date:  1986       Impact factor: 4.553

8.  Advances in the applications of monoclonal antibodies in clinical oncology. Abstracts.

Authors: 
Journal:  Br J Cancer       Date:  1984-10       Impact factor: 7.640

9.  Advances in the applications of monoclonal antibodies in clinical oncology. University of London Royal Postgraduate Medical School. 8th-10th May, 1985. Abstracts.

Authors: 
Journal:  Br J Cancer       Date:  1985-10       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.